home
Borreliosi
Condroprotezione
Artrosi
Artrite Reumatoide
 
 
 
 


 

CONDROPROTEZIONE

 



STUDI DI CONDROPROTEZIONE
NELL'ARTROSI E NELL'ARTROSI EROSIVA

1- GGGs in therapy of tibiofibular
osteoarthritis of the knee. Rovetta G.
Drugs under Experimental and Clinical
Research, 17, 1, 1991.

2- Osteoartrosi erosiva, infiammatoria
e anchilosante delle mani. Rovetta G.,
Bianchi G., Monteforte P., Ghirardo G.,
Bruzzone M., Buffrini L. Riv. It. Biol.
Med. 13: 79-175, 1993.

3- Joint failure in erosive osteoarthritis
of the hands. Rovetta G, Bianchi G,
Monteforte P. Int J Tiss Reac XVII,
33-42, 1995.

4- 1000 pazienti osteoartrosici
in trattamento con GGGs: valutazione
del dolore articolare. Monteforte P,
Guglielmi L, Innocenti M, Rovetta G.
Min. Med., 86, 175-180, 1995.

5- Galactosaminoglycuronglycane
sulfate in erosive osteoarthritis
of the hands: early diagnosi,
early treatment. Rovetta G,
Monteforte P. In. J. Tiss.
React. XVIII (1) 43-46, 1996.

6- Rapidly destructive interphalangeal
osteoarthritis of the hands
(erosive osteoarthritis).
Rovetta G. Jap J Rheum. 1996;
6, 2: 155-168.


7- Quantitative ultrasound of the
proximal phalanges: reproducibility
in erosive and nodal osteoarthritis
of the hands. Rovetta G, Battista S,
Brignone A, Monteforte P., Int J
Tissue React. 1999;21(4):121-7.


8- Chondrotinsulfate in erosive
osteoarthritis of the hands.
Rovetta G,
Monteforte P., Molfetta G., Balestra V.
Int J Tissue React 2002 XXIV (1)
73-76 . l

 

 

TERAPIA DELL'ARTROSI EROSIVA DELLE MANI CON GGGs

Rovetta G Monteforte P Int-J-Tissue-React. 1996; 18(1): 43-6

Galactosaminoglycuronglycan sulfate in erosive osteoarthritis of the hands: early diagnosis, early treatment.

This study examined the effect of an oral chondroprotective drug, galactosaminoglycuronglycan sulfate (GAGs), on the evolution of erosive osteoarthritis of the hands (EOA). Twenty-four patients affected with EOA of the hands were evaluated. The patients had painful, frank arthritis of DIP and PIP joints; X-rays reduced joint space; X-rays central joint erosions; positive joint scintiscan, in absence of other inflammatory and erosive arthropathies. Twelve patients were treated with a chondroprotective drug, GAGs 800 mg/ die; twelve patients were the control group. The results at two years documented that the GAGs treatment influenced certainly joint pain and doubtfully bone scintiscan in EOA.

 

 

nt J Tissue React 2002;24(1):29-32 Related Articles, Books, LinkOut

Chondroitin sulfate in erosive osteoarthritis of the hands.

Rovetta G, Monteforte P, Molfetta G, Balestra V.

Department of Rheumatology, DISEM, University of Genova Medical School, Italy.

The aim of this study was to evaluate the joint count for erosions in patients with erosive osteoarthritis (EOA) of the hands treated with 800 mg/day of orally administered chondroitin sulfate plus naproxen, compared with that of patients administered naproxen only. Twenty-four consecutive patients (22 women and two men, mean age 53.0 +/- 6) suffering from symptomatic OA and with radiographic characteristics of EOA were studied. The patients were divided into two groups of 12 patients each. The first group took naproxen 500 mg/day only. The second group was treated with chondroitin sulfate 800 mg/day orally plus naproxen 500 mg/day. Radiological hand examinations were performed at baseline and again after 12 and 24 months. In both groups, the joint count for erosions showed a general tendency to increase over time. Progression of erosions at 24 months was lower in patients treated with 800 mg/day chondroitin sulfate plus naproxen than in patients taking naproxen only (p <0.05). Chondroitin sulfate failed to stop the usual time-associated progression in the number of finger joints presenting erosions in EOA of the hands. It was, however, associated with a lower increase in the number of finger joints with erosions detected after 2 years of radiological observation.

 
©2002 webtemplateszone.com     free web templates at webtemplateszone.com